Article: Nicotinamide Riboside Restores Intestinal Health and Mitochondrial Function in Colitis: Preclinical Findings

PrevNext
Digestive/Gut Health Gastrointestinal Diseases Preclinical

Nicotinamide Riboside Restores Intestinal Health and Mitochondrial Function in Colitis: Preclinical Findings

Synopsis

Reduced levels of PGC1α, a key regulator of cellular energy, contribute to inflammatory bowel disease (IBD). In both mice with experimental colitis and humans with ulcerative colitis, NAD+ levels in the intestinal lining were significantly lowered, while the activity of the NAD-consuming enzyme PARP1 was increased. Treatment with nicotinamide riboside (NR), an NAD+ precursor, restored NAD+ levels, improved mitochondrial function, increased active PGC1α, and reduced disease severity. However, mice lacking PGC1α in the intestinal lining did not benefit, showing that PGC1α is essential for these effects. These findings suggest that boosting NAD+ with NR could be a promising strategy for supporting intestinal health in IBD.

Journal

Frontiers in Immunology

Share

Read more

Cardiovascular Disease

Nicotinamide Riboside Restores Mitochondrial Function and Improves Heart Failure with Preserved Ejection Fraction: Preclinical Findings

SynopsisHeart Failure with Preserved Ejection Fraction (HFpEF) is a serious heart condition without effective treatments. In a mouse model of HFpEF, researchers found impaired mitochondrial fatty a...

Read more
Muscle Health

Nicotinamide Riboside Restores Exercise Capacity and Mitochondrial Function in Barth Syndrome: Preclinical Findings

SynopsisBarth syndrome, caused by tafazzin mutation, leads to mitochondrial dysfunction and severe exercise intolerance. In a Drosophila model, NR supplementation restored exercise capacity and mit...

Read more